DIWALI SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo

SRD vs SUDARSHAN: Stock Comparison

SHANKAR LAL RAMPAL vs SUDARSHAN PHARMA INDUpdated 13 Nov 26, 4:08 PM ISTNSE & company filings

SHANKAR LAL RAMPAL shows a lower P/E, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

SRD leads 6; SUDARSHAN leads 1 of 7

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

SRDSUDARSHAN

Valuation lens

What price are you paying?

Market CapContext only
₹300 Cr
₹0 Cr
P/E RatioSRD has the lower reading
17.93x ✓
28.27x
P/B RatioSRD has the lower reading
1.97x ✓
4.11x
EPSSUDARSHAN has the higher reading
₹0.09
₹0.32 ✓
Book ValueContext only
₹19.19
₹6.14
Dividend YieldSRD has the higher reading
0.11% ✓
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

P/E Ratio
SRD has a lower P/E
17.93x vs 28.27x
P/B Ratio
SRD has a lower P/B
1.97x vs 4.11x
EPS
SUDARSHAN has higher earnings per share
₹0.32 vs ₹0.09
Dividend Yield
SRD has a higher dividend yield
0.11% vs 0%
Revenue Growth (TTM YoY)
SRD has faster revenue growth
30.5% vs 0%
EPS Growth (TTM YoY)
SRD has faster EPS growth
92.8% vs 0%
Net Margin
SRD has a higher net margin
2.9% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricSRDSUDARSHAN
SectorChemicals—
IndustryTrading - Chemicals—

Price

MetricSRDSUDARSHAN
Live Price₹46.75₹32.71
Day Change4.19%0.03%
Volume67,41292,985
52-Week High₹71₹39.3
52-Week Low₹35.92₹31.01
Distance from 52W High-34.15%-16.77%

Valuation

MetricSRDSUDARSHAN
Market Cap₹300 Cr₹0 Cr
P/E Ratio17.93x28.27x
P/B Ratio1.97x4.11x
EPS₹0.09₹0.32
Book Value₹19.19₹6.14
Dividend Yield0.11%0%

Growth

MetricSRDSUDARSHAN
Revenue Growth (TTM YoY)30.5%0%
EPS Growth (TTM YoY)92.8%0%
Qtr Sales Growth—24.4%
Qtr Profit Growth—38.7%

Profitability & Leverage

MetricSRDSUDARSHAN
ROE10.99%—
ROCE9.7%—
Net Margin2.9%0%
Operating Margin4.16%—
Debt to Equity0.21x—

Shareholding

As of Sep 2026 • change vs previous quarter
MetricSRDSUDARSHAN
Promoter Holding73.61%57.81%▼ 1.12 pp
FII Holding0.04%21.95%▲ 2.57 pp
DII Holding0%0%
Public Holding26.36%20.19%▼ 1.45 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SHANKAR LAL RAMPAL and SUDARSHAN PHARMA IND.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.